ICON Public Limited Company (ICLR)
NASDAQ: ICLR · Real-Time Price · USD
166.44
-2.75 (-1.63%)
At close: Aug 1, 2025, 4:00 PM
166.46
+0.02 (0.01%)
After-hours: Aug 1, 2025, 7:32 PM EDT
CTI BioPharma Revenue
ICON Public Limited Company had revenue of $2.02B in the quarter ending June 30, 2025, a decrease of -4.85%. This brings the company's revenue in the last twelve months to $8.09B, down -2.91% year-over-year. In the year 2024, ICON Public Limited Company had annual revenue of $8.28B with 1.99% growth.
Revenue (ttm)
$8.09B
Revenue Growth
-2.91%
P/S Ratio
1.67
Revenue / Employee
$193,074
Employees
41,900
Market Cap
12.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.28B | 161.50M | 1.99% |
Dec 31, 2023 | 8.12B | 378.79M | 4.89% |
Dec 31, 2022 | 7.74B | 2.26B | 41.24% |
Dec 31, 2021 | 5.48B | 2.68B | 95.93% |
Dec 31, 2020 | 2.80B | -8.55M | -0.30% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ICLR News
- 8 days ago - ICON Public Limited Company (ICLR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - ICON: Lower Guidance Downside And Expanded Repurchase Plan - Seeking Alpha
- 9 days ago - ICON Announces Results of Annual General Meeting - Business Wire
- 9 days ago - ICON Reports Second Quarter 2025 Results - Business Wire
- 16 days ago - ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report - Business Wire
- 25 days ago - ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability - Business Wire
- 5 weeks ago - ICON: With A 57% Drop, Trump Legislation, And Debt Reduction, Is The Stock Undervalued? - Seeking Alpha
- 5 weeks ago - ICON plc Schedules Second Quarter 2025 Earnings Conference Call - Business Wire